Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Clinical trial NCT06001788 · RECRUITING

Trial details

NCT number: NCT06001788
Sponsor: Kura Oncology, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

AML AML With Mutated NPM1 Hematologic Malignancy KMT2Ar NPM1 Mutation MLL Rearrangement Leukemia Acute Myeloid Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Acute Leukemia Neoplasms by Histologic Type

Start date: 2024-02-22
Primary completion: 2026-12-01
Enrollment: 171

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.